Source link : https://www.newshealth.biz/health-news/glp-2-analog-reduces-need-for-parenteral-support-in-patients-with-rare-gi-condition/
WASHINGTON — Apraglutide, an investigational long-acting synthetic GLP-2 analog, reduced the need for parenteral support in patients with short bowel syndrome and intestinal failure (SBS-IF), a phase III randomized trial showed. At 24 weeks, the relative change from baseline in weekly parenteral support volume was -25.5% for patients who received a weekly subcutaneous dose of […]
Author : News Health
Publish date : 2024-05-23 18:44:38
Copyright for syndicated content belongs to the linked Source.